PURPOSE: Primary immunodeficiencies (PIDs) are a heterogeneous group of disorders characterized mainly by recurrent infections. Late diagnosis remains as one of the main issues to solve. We aimed to increase PID diagnosis in Aguascalientes, a 1.3 million inhabitants state in the center of Mexico, and to describe the clinical features of such patients. METHODS: We developed an educational program for health personnel and general public; patients with possible PID were referred to a State University clinical center from December 2011 to December 2012. The patients were evaluated at the clinic and their definitive diagnosis pursued through laboratory, molecular and genetic assays. We describe the findings of those patients and analyze the impact of the program in terms of number of referrals. RESULTS: After 41 talks and 12 media appearances 151 patients were referred for evaluation. Fifteen (9.9%) were diagnosed with PID: five (33%) had antibody deficiencies, seven (47%) Well-defined syndromes, two (13%) Severe combined Immunodeficiency (SCID) and one case (7%) of an innate immune deficiency. All of the 15 PID patients had been referred by physicians, as opposed to the public. We estimated a "number needed to teach" of 75 physicians to get one PID patient referral. CONCLUSION: Educational programs are a fundamental part of the global efforts to increase PID diagnosis and care. To be successful, such programs should include public relations, reach for first-contact physicians, and aim to develop an efficient referral network with molecular diagnostic capability. Enhancing medical knowledge on PID is a successful strategy to improve early diagnosis and treatment.
PURPOSE:Primary immunodeficiencies (PIDs) are a heterogeneous group of disorders characterized mainly by recurrent infections. Late diagnosis remains as one of the main issues to solve. We aimed to increase PID diagnosis in Aguascalientes, a 1.3 million inhabitants state in the center of Mexico, and to describe the clinical features of such patients. METHODS: We developed an educational program for health personnel and general public; patients with possible PID were referred to a State University clinical center from December 2011 to December 2012. The patients were evaluated at the clinic and their definitive diagnosis pursued through laboratory, molecular and genetic assays. We describe the findings of those patients and analyze the impact of the program in terms of number of referrals. RESULTS: After 41 talks and 12 media appearances 151 patients were referred for evaluation. Fifteen (9.9%) were diagnosed with PID: five (33%) had antibody deficiencies, seven (47%) Well-defined syndromes, two (13%) Severe combined Immunodeficiency (SCID) and one case (7%) of an innate immune deficiency. All of the 15 PIDpatients had been referred by physicians, as opposed to the public. We estimated a "number needed to teach" of 75 physicians to get one PIDpatient referral. CONCLUSION: Educational programs are a fundamental part of the global efforts to increase PID diagnosis and care. To be successful, such programs should include public relations, reach for first-contact physicians, and aim to develop an efficient referral network with molecular diagnostic capability. Enhancing medical knowledge on PID is a successful strategy to improve early diagnosis and treatment.
Entities:
Keywords:
Primary immunodeficiency diseases; awareness; educational program
Authors: A Condino-Neto; J L Franco; F J Espinosa-Rosales; L E Leiva; A King; O Porras; M Oleastro; L Bezrodnik; A S Grumach; B T Costa-Carvalho; R U Sorensen Journal: Allergol Immunopathol (Madr) Date: 2012-03-23 Impact factor: 1.667
Authors: L E Leiva; L Bezrodnik; M Oleastro; A Condino-Neto; B T Costa-Carvalho; A Sevciovic Grumach; F J Espinosa-Rosales; J Luis Franco; A King; J Inostroza; A Quezada; O Porras; R U Sorensen Journal: Allergol Immunopathol (Madr) Date: 2011-02-22 Impact factor: 1.667
Authors: Lily E Leiva; Marta Zelazco; Matías Oleastro; Magda Carneiro-Sampaio; Antonio Condino-Neto; Beatriz Tavares Costa-Carvalho; Anete Sevciovic Grumach; Arnoldo Quezada; Pablo Patiño; José Luis Franco; Oscar Porras; Francisco Javier Rodríguez; Francisco Javier Espinosa-Rosales; Sara Elva Espinosa-Padilla; Diva Almillategui; Celia Martínez; Juan Rodríguez Tafur; Marilyn Valentín; Lorena Benarroch; Rosy Barroso; Ricardo U Sorensen Journal: J Clin Immunol Date: 2006-12-27 Impact factor: 8.317
Authors: S Gilad; L Chessa; R Khosravi; P Russell; Y Galanty; M Piane; R A Gatti; T J Jorgensen; Y Shiloh; A Bar-Shira Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: Benjamin Gathmann; Nizar Mahlaoui; Laurence Gérard; Eric Oksenhendler; Klaus Warnatz; Ilka Schulze; Gerhard Kindle; Taco W Kuijpers; Rachel T van Beem; David Guzman; Sarita Workman; Pere Soler-Palacín; Javier De Gracia; Torsten Witte; Reinhold E Schmidt; Jiri Litzman; Eva Hlavackova; Vojtech Thon; Michael Borte; Stephan Borte; Dinakantha Kumararatne; Conleth Feighery; Hilary Longhurst; Matthew Helbert; Anna Szaflarska; Anna Sediva; Bernd H Belohradsky; Alison Jones; Ulrich Baumann; Isabelle Meyts; Necil Kutukculer; Per Wågström; Nermeen Mouftah Galal; Joachim Roesler; Evangelia Farmaki; Natalia Zinovieva; Peter Ciznar; Efimia Papadopoulou-Alataki; Kirsten Bienemann; Sirje Velbri; Zoya Panahloo; Bodo Grimbacher Journal: J Allergy Clin Immunol Date: 2014-02-28 Impact factor: 10.793
Authors: Waleed Al-Herz; Aziz Bousfiha; Jean-Laurent Casanova; Helen Chapel; Mary Ellen Conley; Charlotte Cunningham-Rundles; Amos Etzioni; Alain Fischer; Jose Luis Franco; Raif S Geha; Lennart Hammarström; Shigeaki Nonoyama; Luigi Daniele Notarangelo; Hans Dieter Ochs; Jennifer M Puck; Chaim M Roifman; Reinhard Seger; Mimi L K Tang Journal: Front Immunol Date: 2011-11-08 Impact factor: 7.561
Authors: Beatriz Tavares Costa-Carvalho; Anete Sevciovic Grumach; José Luis Franco; Francisco Javier Espinosa-Rosales; Lily E Leiva; Alejandra King; Oscar Porras; Liliana Bezrodnik; Mathias Oleastro; Ricardo U Sorensen; Antonio Condino-Neto Journal: J Clin Immunol Date: 2013-11-16 Impact factor: 8.317